WISTA LAB LTD has a total of 320 patent applications. It decreased the IP activity by 83.0%. Its first patent ever was published in 1996. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are LIGAND PHARMACEUTICALS INCORPORATED, TEVA PHARMACEUTICAL INDUSTRIES LTD and Grünenthal GmbH .
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 39 | |
#2 | United States | 37 | |
#3 | Australia | 34 | |
#4 | China | 30 | |
#5 | Canada | 26 | |
#6 | Hong Kong | 23 | |
#7 | WIPO (World Intellectual Property Organization) | 20 | |
#8 | United Kingdom | 17 | |
#9 | Republic of Korea | 14 | |
#10 | Malaysia | 14 | |
#11 | Brazil | 13 | |
#12 | Mexico | 12 | |
#13 | Singapore | 11 | |
#14 | Japan | 10 | |
#15 | Israel | 6 | |
#16 | Hungary | 5 | |
#17 | Slovenia | 3 | |
#18 | EAPO (Eurasian Patent Organization) | 2 | |
#19 | Taiwan | 2 | |
#20 | Argentina | 1 | |
#21 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Measurement | |
#5 | Basic materials chemistry | |
#6 | Medical technology | |
#7 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Wischik Claude Michel | 178 |
#2 | Storey John Mervyn David | 162 |
#3 | Harrington Charles Robert | 116 |
#4 | Sinclair James Peter | 107 |
#5 | Horsley David | 96 |
#6 | Marshall Colin | 92 |
#7 | Rickard Janet Elizabeth | 89 |
#8 | Baddeley Thomas Craven | 53 |
#9 | Clunas Scott | 47 |
#10 | Wischik Damon Jude | 37 |
Publication | Filing date | Title |
---|---|---|
GB202016955D0 | Therapeutic treatments | |
GB202016957D0 | Beneficial treatment | |
GB202010679D0 | Methods of providing modulators of Tau aggregation | |
GB202010620D0 | System | |
GB202010652D0 | Anti-tau antibodies | |
GB202006659D0 | Therapeutic treatments | |
AU2019308873A1 | Optimised dosage of diaminophenothiazines in populations | |
GB201909506D0 | Synaptopathies | |
GB201909454D0 | Enhancers | |
GB201909458D0 | Optimised dosage of diaminophenothiazines in populations | |
GB201909493D0 | Therapeutic interactions | |
GB201812193D0 | Optimised dosage of diaminophenothiazines in populations | |
US2020016165A1 | Administration and dosage of diaminophenothiazines | |
GB201710382D0 | Administration and dosage of Diaminophenothiazines | |
GB201621817D0 | Methods of chemical synthesis | |
GB201614834D0 | Treatment of dementia | |
GB201612863D0 | Administration and dosage of diaminophenothiazines | |
AU2016202982A1 | Crystalline methylthionium chloride (methylene blue) hydrates | |
GB201512678D0 | Methods of chemical synthesis | |
AU2014280990A1 | 3,6-disubstituted xanthylium salts as medicaments |